Loading stock data…
NBIX
$131.78+0.11 (+0.08%)
Market ClosedLast close May 1
Neurocrine Biosciences, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Neurocrine Biosciences, Inc. in the Healthcare sector is trading at $131.78. The stock is currently 18% below its 52-week high of $160.18, remaining 4.0% below its 200-day moving average. Technical signals show neutral RSI of 61 and bullish MACD crossover, explaining why NBIX maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 61) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$131.78
Potential Downside
28.3%
Whystock Fair Value$94.49
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus27 analysts
Mean target$185.65+40.9%
Range$140.00 – $250.65
Fundamentals
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dy...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$13.19B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
28.09
Beta
Defensive asset. Lower volatility than the S&P 500.
0.35
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
10.71%
Volume
Today's trading volume
619,899
Recent News
Neurocrine Biosciences (NBIX) Announces First Presentation of New Two-Year Data From Phase 3 CAHtalyst® Adult Study
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the best drug stocks to buy according to analysts. On April 22, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced the first presentation of new two-year data from the Phase 3 CAHtalyst® Adult study exhibiting sustained, substantial reductions in glucocorticoid (GC) doses in adults with classic congenital adrenal hyperplasia treated with CRENESSITY®. […]
Earnings Preview: Collegium Pharmaceutical (COLL) Q1 Earnings Expected to Decline
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
US High Growth Tech Stocks To Watch In Your Portfolio
Over the last 7 days, the United States market has remained flat, yet it is up 30% over the past year with earnings forecast to grow by 16% annually. In this environment, identifying high growth tech stocks that align with these promising trends can be a valuable addition to a diversified portfolio.
3 Reasons Growth Investors Will Love Neurocrine (NBIX)
Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market.
Wall Street Analysts Think Neurocrine (NBIX) Could Surge 38.79%: Read This Before Placing a Bet
The consensus price target hints at a 38.8% upside potential for Neurocrine (NBIX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.